Start up. Grow up. Succeed.

Sanofi and MAB Discovery sign collaboration agreement for the

Sanofi and MAB Discovery GmbH entered into a research and license agreement in the field of monoclonal antibodies.

Neuried, Germany;  December 14, 2015:  Sanofi and MAB Discovery GmbH  announced today that  they  have  entered  into  a  research  and  license  agreement  in  the  field  of  monoclonal antibodies.  Within  the  scope  of  this  collaboration,  MAB  Discovery  will  develop  therapeutic antibodies  for  selected  targets  of  Sanofi  and  thus  support  Sanofi  in  the  development  of antibody-based  therapies.  Sanofi  will  in  return  receive  high-quality  antibodies  with  the  aim  of identifying active substances for a number of diseases that are difficult to treat. Sanofi and MAB Discovery  have  agreed  on  a  fee  for  the  research  activities.  When  specific  milestones  are achieved, the agreement provides for further performance-related payments to MAB Discovery. Financial details of the agreement were not disclosed.

"Through this agreement  with MAB Discovery we have found a strong collaboration in Germany to support us in bringing forward various antibody research projects with the help of its unique technology platform", said Prof. Dr. Jochen Maas, Head of Research & Development of Sanofi Germany.

"This  agreement  is  an  important  confirmation  for  the  quality  of  our  outstanding  research platform. MAB Discovery is a renowned antibody specialist who focuses primarily on previously refractory  diseases  with  strong  medical  needs.  Our  in-vivo  platform  based  on  a  new  highthroughput  screening  processes  could  enable  the  development  of  best-in-class  antibody therapies", said Dr. Stephan Fischer, CEO of MAB Discovery.

MAB Discovery uses its technology platform for the discovery of antibodies  in vivo, which  are based on natural immune responses in rabbits.  Subsequently,  the Company employs  state-ofthe-art technology for the cloning of  antibodies directly from  B-cells (a type of white blood cell). Applying new high-throughput screening processes,  enables  MAB Discovery  to identify  highly  active antibodies. These  identified antibodies cover a large number of different target structures (epitopes).  The  binding  of  medically  active  substances  to  endogenous  targets  is  essential  to fight diseases.  The technology employed by MAB Discovery generates a large variety of  antibodies. Of these antibodies,  those  with  the  highest  possible  biological  effectiveness  can  then  be  selected  and further  developed.  This  technology  has  already  been  used  successfully  for  targets  that  are difficult  to  address.  One  major  advantage,  among  others,  is  that  it  requires  neither  timeconsuming  optimization  of  the  target  binding,  nor  the  development  of  so-called  surrogate antibodies.


About MAB Discovery
MAB  Discovery  was  founded  in  Munich,  Germany  in  October  2010.  The  team  represents  a group  of  scientists  out  of  Roche  Biologicals  R&D  with  extensive  experience  in  developing biologically based therapeutics. MAB Discovery follows a flexible collaboration-based business model to meet the needs of their clients  and has  ongoing partnerships with several biotech and pharma companies.

For more information please visit www.mabdiscovery.com.

 

About Sanofi
Sanofi,  a  global  healthcare  leader,  discovers,  develops  and  distributes  therapeutic  solutions focused  on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is  listed  in  Paris  (EURONEXT:  SAN)  and  in  New  York  (NYSE:  SNY).  

For  more  information please visit: www.sanofi.com
MAB Discovery:
Dr. Anton Haselbeck, SVP
+49 89 990 178-0
Anton.Haselbeck[at]mabdiscovery.com

For media inquiries:
MC Services AG
Katja Arnold
Phone: +49 89 210 228-40
katja.arnold[at]mc-services.eu


Forward Looking Statements
This press release  contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and  statements  regarding  future  performance.  Forward-looking  statements  are  generally  identified  by  the  words “expects”,  “anticipates”,  “believes”,  “intends”,  “estimates”,  “plans”  and  similar  expressions.  Although  Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable,  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which  are  difficult  to  predict  and  generally  beyond  the  control  of  Sanofi,  that  could  cause  actual  results  and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the  availability  or  commercial  potential  of  such  product  candidates,  the  absence  of  guarantee  that  the  product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest  rates,  the  impact  of cost  containment initiatives  and  subsequent changes  thereto ,  the  average  number  of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi,  including  those  listed  under  “Risk  Factors”  and  “Cautionary  Statement  Regarding  Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.